Patients with systemic lupus erythematosus (SLE) who develop pneumonia have a high risk of adverse prognosis, according to a new study. The findings also revealed that common scales of pneumonia severity can misclassify cases of SLE and pneumonia as low risk.
In The Lancet, Ronald van Vollenhoven and colleagues report a positive multicentre double-blind phase 2 randomised, placebo-controlled trial with ustekinumab, an anti-interleukin-12/23 (IL-12/23) monoclonal antibody, in 102 patients aged 18–75 years with active systemic lupus erythematosus (93 women and nine men).
Patients with systemic lupus erythematosus in remission for five or more years are at a lower risk of cardiovascular disease than those with shorter remission times or who fail to enter remission, a retrospective study reports.
The study, “Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study,” was published in Clinical Rheumatology.
The transplantation of human placental cells was found to suppress immune and inflammatory responses in a mouse model of systemic lupus erythematosus (SLE), suggesting a potential new therapeutic strategy for lupus, a study shows.
The study, “Therapeutic effect of human amniotic epithelial cells in murine models of Hashimoto’s thyroiditis and Systemic lupus erythematosus,” was published in the journal Cytotherapy.
The aim of this study was to determine the prevalence and predictors of medication nonadherence among patients with systemic lupus erythematosus (SLE) in Sichuan. A cross-sectional investigation was performed. Participants were recruited by consecutive sampling from the Rheumatic Clinic of a university hospital.
Virgin olive oil, especially its phenol components, showed anti-inflammatory properties in mice with systemic lupus erythematosus (SLE) and in human immune cells, according to a new Spanish study. The findings suggest future use in SLE treatment.
The research, “Virgin olive oil and its phenol fraction modulate monocyte/macrophage functionality: a potential therapeutic strategy in the treatment of systemic lupus erythematosus,” was published in the British Journal of Nutrition.
Patients with both scleroderma and systemic lupus erythematosus (SLE) are younger at diagnosis, are more often women, and have less skin manifestations, but most importantly, show similar survival rates as those without lupus, according to a study.
The study, “Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome,” was published in The Journal of Rheumatology.
In China, mortality rates are higher among women with systemic lupus erythematosus(SLE) than men, with infection being the leading cause of death, a study reports.
According to the researchers, risk factors for poorer outcomes include older age at disease onset, infection, autoimmune anemia, low platelet levels, and pulmonary arterial hypertension.
Lupus affects nine times more women than men. Experts know that lupus erythematosus, SLE, or lupus affects many more women than men, but none of them can explain why. Now that University of Houston biomedical engineer Chandra Mohan has the funding, he has set out to determine why.
Prof. Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, has $2 million to solve the mystery.
Cardiovascular disease is a leading cause of death in patients with lupus, a systemic autoimmune disease. In a new study in Arthritis & Rheumatology—a journal published by Wiley on behalf of the American College of Rheumatology—imaging tests revealed signs of cardiac impairment in patients newly diagnosed with lupus, even before any symptoms of chest discomfort.